Blog | HemaCare

Lung Cancer Patients Live Longer with Drug Targeting T cells

Feb 24, 2016 1:00:46 PM / by Daisy posted in Cancer Immunology, clinical trial, PD-1, PD-L1, pembrolizumab

0 Comments

Pembrolizumab, a newer drug, harnesses T cells to tackle cancer. For certain lung cancer patients, this means having twice the lifespan than that accorded by chemotherapy! 

For patients battling lung cancer, the majority are of the non-small-cell lung carcinoma (NSCLC) subtype. Among these, a subgroup of tumors produce a protein, PD-L1, which enables escape from attack by the patient’s immune system (see here). Specifically, PD-L1 binds to PD-1 receptors on T cells, thereby preventing T cells from activating, proliferating, and/or producing cytokines, so that T cells do not mount an attack towards the PD-L1-positive tumor cells.

Read More

Cancer Drug Targeting T cells: The CTLA-4 Checkpoint Inhibitor

Mar 23, 2015 1:00:53 PM / by Daisy posted in cancer drug, cancer immunotherapy, checkpoint inhibitors, CTLA-4, PD-1, research

0 Comments

Immune checkpoints modulate either the activation or downplay of T cells but can be manipulated by cancer cells. We can strike back with newer drugs.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts